Heterogeneity of Large Cell Carcinoma of the Lung An Immunophenotypic and miRNA-Based Analysis

被引:40
|
作者
Barbareschi, Mattia [1 ,2 ]
Cantaloni, Chiara [2 ]
Del Vescovo, Valerio [4 ]
Cavazza, Alberto [5 ]
Monica, Valentina [6 ,7 ]
Carella, Rodolfo [8 ]
Rossi, Giulio [9 ]
Morelli, Luca
Cucino, Alberto
Silvestri, Massimo [3 ]
Tirone, Giuseppe [3 ]
Pelosi, Giuseppe [10 ]
Graziano, Paolo [11 ]
Papotti, Mauro [6 ,7 ]
Dalla Palma, Paolo
Doglioni, Claudio [12 ]
Denti, Michela Alessandra [4 ]
机构
[1] Santa Chiara Hosp, Lab Mol Pathol, Unit Surg Pathol, I-38122 Trento, Italy
[2] Santa Chiara Hosp, Trentino Biobank, Unit Surg Pathol, I-38122 Trento, Italy
[3] Santa Chiara Hosp, Surg Unit, I-38122 Trento, Italy
[4] Univ Trento, Ctr Integrat Biol, Trento, Italy
[5] Arcispedale S Maria Nuova, Unit Pathol Anat, Reggio Emilia, Italy
[6] San Luigi Hosp, Unit Pathol Anat, Orbassano, Italy
[7] Univ Turin, Orbassano, Italy
[8] S Maurizio Hosp, Unit Surg Pathol, Bolzano, Italy
[9] Azienda Osped Univ Policlin, Sect Pathol Anat, Modena, Italy
[10] Fdn IRCCS Ist Nazl Tumori, Unit Pathol & Lab Med, Milan, Italy
[11] Forlanini Hosp, Anat Pathol Unit, Rome, Italy
[12] S Raffaele Hosp, Unit Surg Pathol, Milan, Italy
关键词
Heterogeneity; Large cell carcinoma; Lung neoplasms; miRNA; Immunophenotype; Adenocarcinoma; Squamous cell carcinoma; TRANSCRIPTION FACTOR-I; NONSMALL CELL; EXPRESSION; P63; MARKER; CANCER; TTF-1; ADENOCARCINOMAS; TUMORS; SUBCLASSIFICATION;
D O I
10.1309/AJCPYY79XAGRAYCJ
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Large cell carcinomas (LCCs) of the lung are heterogeneous and may be of different cell lineages. We analyzed 56 surgically resected lung tumors classified as LCC on the basis of pure morphologic grounds, using a panel of immunophenotypic markers (adenocarcinoma [ADC]-specific, thyroid transcription factor-1, cytokeratin 7, and napsin A; squamous cell carcinoma [SQCC]-specific, p63, cytokeratin 5, desmocollin 3, and Delta np63) and the quantitative analysis of microRNA-205 (microRNA sample score [mRSS]). Based on immunoprofiles 19 (34%) of the cases were reclassified as ADC and 14 (25%) as SQCC; 23 (41%) of the cases were unclassifiable. Of these 23 cases, 18 were classified as ADC and 5 as SQCC according to the mRSS. Our data show that an extended panel of immunohistochemical markers can reclassify around 60% of LCCs as ADC or SQCC. However, a relevant percentage of LCCs may escape convincing immunohistochemical classification, and mRSS could be used for further typing, but its clinical relevance needs flirt her confirmation.
引用
收藏
页码:773 / 782
页数:10
相关论文
共 50 条
  • [1] Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis
    Barbareschi, M.
    Cantaloni, C.
    Del Vescovo, V.
    Cavazza, A.
    Carella, R.
    Rossi, G.
    Pelosi, G.
    Papotti, M.
    Denti, M. A.
    [J]. VIRCHOWS ARCHIV, 2011, 459 : S53 - S54
  • [2] MiRNA-based Therapeutics for Lung Cancer
    Wu, Miaowei
    Wang, Guosheng
    Tian, Wei
    Deng, Yongchuan
    Xu, Yibing
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (39) : 5989 - 5996
  • [3] A plasma miRNA-based classifier for small cell lung cancer diagnosis
    Saviana, Michela
    Romano, Giulia
    McElroy, Joseph
    Nigita, Giovanni
    Distefano, Rosario
    Toft, Robin
    Calore, Federica
    Le, Patricia
    Morales, Daniel Del Valle
    Atmajoana, Sarah
    Deppen, Stephen
    Wang, Kai
    Lee, L. James
    Acunzo, Mario
    Nana-Sinkam, Patrick
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] MiRNA-based Therapeutic Strategy in Lung Cancer
    Li, Guang
    Fang, Jing
    Wang, Ying
    Wang, Hu
    Sun, Cheng-Cao
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (39) : 6011 - 6018
  • [5] A miRNA-based classification of renal cell carcinoma subtypes by PCR and in situ hybridization
    Di Meo, Ashley
    Saleeb, Rola
    Wala, Samantha J.
    Khella, Heba W.
    Ding, Qiang
    Zhai, Haiyan
    Krishan, Kalra
    Krizova, Adriana
    Gabril, Manal
    Evans, Andrew
    Brimo, Fadi
    Pasic, Maria D.
    Finelli, Antonio
    Diamandis, Eleftherios P.
    Yousef, George M.
    [J]. ONCOTARGET, 2018, 9 (02) : 2092 - 2104
  • [6] MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?
    Yang, Han
    Liu, Yufang
    Chen, Longqing
    Zhao, Juanjuan
    Guo, Mengmeng
    Zhao, Xu
    Wen, Zhenke
    He, Zhixu
    Chen, Chao
    Xu, Lin
    [J]. BIOMOLECULES, 2023, 13 (06)
  • [7] A Novel miRNA-Based Model Can Predict the Prognosis of Clear Cell Renal Cell Carcinoma
    Wu, Jiyue
    Zhang, Feilong
    Zhang, Jiandong
    Sun, Zejia
    Hao, Changzhen
    Cao, Huawei
    Wang, Wei
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [8] A novel miRNA-based classification model of risks and stages for clear cell renal cell carcinoma patients
    Dessie, Eskezeia Y.
    Tsai, Jeffrey J. P.
    Chang, Jan-Gowth
    Ng, Ka-Lok
    [J]. BMC BIOINFORMATICS, 2021, 22 (SUPPL 10)
  • [9] A novel miRNA-based classification model of risks and stages for clear cell renal cell carcinoma patients
    Eskezeia Y. Dessie
    Jeffrey J. P. Tsai
    Jan-Gowth Chang
    Ka-Lok Ng
    [J]. BMC Bioinformatics, 22
  • [10] Fluid-specific miRNA-based signatures for lung cancer screening
    Casagrande, Giovanna
    Chiarantano, Rodrigo
    Polo, Alexia
    Laus, Ana Carolina
    Tegami, Isabella
    Cabral, Eduardo
    Filatieri, Angela
    Oliveira, Rachid
    Da Silva, Luciane Sussuchi
    Reis, Rui
    Leal, Leticia
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62